ANXA5 and prostate carcinoma: To determine if CUDC‐907 treatment causes death of prostate cancer cells, 22Rv1 and LNCaP cells were treated with 0‐200 nmol/L CUDC‐907 for 48 hours and then subjected to Annexin V/PI staining and flow cytometry analysis.